ArticleEuropean journal of clinical pharmacology2025
Administration of polyethylene glycol in critically ill patients with acute myocardial infarction: a retrospective propensity score-matched cohort study.
Article in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePolyethylene glycol (PEG) is commonly administered in acute myocardial infarction (AMI) cases, though its clinical efficacy remains unclear. This study investigated whether PEG treatment enhances survival outcomes in AMI patients.
methodsThis retrospective study analyzed data from the American Medical Information Mart for Intensive Care (MIMIC)-IV database, examining critically ill patients with AMI. The exposure was defined as PEG administration during hospitalization. The primary endpoints were 7-day and in-hospital all-cause mortality. External validation was performed using the eICU 2.0 database.
resultsThe study included 2422 participants before propensity score matching (PSM) and 1730 after matching. Multivariate Cox regression analysis prior to PSM revealed that PEG administration significantly lowered 7-day (HR = 0.247, 95% CI 0.179-0.341, p < 0.001) and in-hospital (HR = 0.422, 95% CI 0.347-0.512, p < 0.001) all-cause mortality. Post-PSM analysis produced consistent findings, with PEG administration linked to reduced 7-day (HR = 0.244, 95% CI 0.168-0.354, p < 0.001) and in-hospital (HR = 0.420, 95% CI 0.337-0.524, p < 0.001) mortality. Subgroup analyses indicated PEG's protective effect persisted across all clinical subgroups (all p-interaction > 0.005). External validation using Cox regression further confirmed that PEG administration significantly reduced both in-ICU (HR = 0.353, 95% CI 0.211-0.591, p < 0.001) and in-hospital (HR = 0.403, 95% CI 0.268-0.607, p < 0.001) mortality.
conclusionPEG administration improved survival outcomes in critically ill AMI patients, reducing both 7-day and in-hospital all-cause mortality.
Indexed as
Identifiers
40745112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.